Diprogulic acid (Dikegulac) is used as a precursor in vitamin C synthesis. It is plant growth regulator for hedges. Dikegulac is used to differentially kill terminal apices, and it analogously inhibits basic metabolic functions in dividing cells, but not stationary cells, in suspension culture. At the lowest concentrations, dikegulac partially suppresses division of the isolated tobacco protoplasts. Higher concentrations are required to produce visual cytoplasmic damage to the protoplasts, which probably first occurs at the level of the plasmalemma, as the vacuoles can be released intact. Later, tonoplast disruption occurs. It does not inhibit mature leaves.

Metoxepin was developed as an antiemetic, neuroleptic and antihistamine agent. This drug has never been marketed.

Midaglizole (also known as DG 5128) is a α2 adrenoceptor antagonist. Daiichi Pharmaceutical developed this drug as an oral antidiabetic agent and to treat asthma. However, further study of this drug was discontinued.

Mezepine is an antidepressive agent, that has never been marketed.

Milenperone, a dopamine receptor antagonist was studied as an antipsychotic drug. It participated in clinical trials in the management of aggressive behavior in alcoholics and epileptics. Besides, the effect of milenperone was studied for the aggressive behavior of oligophrenic patients. However, information about the further development of the drug is not available.

Midazogrel (CBS-645) is a specific inhibitor of thromboxane synthetase. It inhibits the platelet enzyme in human and is potentially useful as an antithrombotic agent. Midazogrel could be of interest in the treatment of the various diseases in which the pathological role of thromboxane A2 is suspected. However, information about the further development of this drug is not available.

Miloxacin, an antibacterial agent that was used in veterinary. This drug was also studied for the treatment of acute intestinitis. Experiments in vitro have shown that this compound exhibited significant activities against Escherichia coli, Klebsiella pneumonia, Proteus mirabilis, Proteus vulgaris, and less active against a Pseudomonas aeruginosa infection and inactive at the maximum test doses against a Streptococcus pyogenes infection. Information about the current use of miloxacin is not available.

Mitotenamine is benzo[b]thiophene derivative with nucleotoxic activity patented by Shandong Lanjin Biotech Co. for cancer chemotherapy.

An orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and thropomyosin receptor kinase A (TRKA), with potential antineoplastic activity. CDK2/TRKA inhibitor PHA-848125 AC potently inhibits cyclin-dependent kinase 2 (CDK2) and exhibits activity against other CDKs including CDK1 and CDK4, in addition to TRKA. Inhibition of these kinases may result in cell cycle arrest and apoptosis of tumor cells that express these kinases. Milciclib is currently in phase II clinical trials for thymic carcinoma, glioma and liver cancer. The most common adverse events are nausea and asthenia, vomiting, myasthenic syndrome, dehydration, hypophosphatemia, cytolytic hepatitis and plantar fasciitis.